Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis

References

• PascoliniDMariottiSPPokharelGP2002 global update of available data on visual impairment: a compilation of population-based prevalence studiesOphthalmic Epidemiol20041126711515255026
   PubMed Web of Science ®Google Scholar
• FriedmanDSO’ColmainBJMufiozBEye Diseases Prevalence Research Group: prevalence of age-related macular degeneration in the United StatesArch Ophthalmol2004122456457215078675
   PubMed Web of Science ®Google Scholar
• KawasakiRYasudaMSongSJThe prevalence of age-related macular degeneration in Asians- a systematic review and meta-analysisOphthalmology2010117592192720110127
   PubMed Web of Science ®Google Scholar
• WongTChakravarthyUKleinRThe natural history and prognosis of neovascular age-related macular degeneration- a systematic review of the literature and meta-analysisOphthalmology2008115111612617675159
   PubMed Web of Science ®Google Scholar
• ThomasMMousaSSMousaSAComparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degenerationClin Ophthalmol2013749550123503202
   PubMedGoogle Scholar
• EmersonMVLauerAKCurrent and emerging therapies for the treatment of age-related macular degenerationClin Ophthalmol20082237738819668729
   PubMedGoogle Scholar
• GragoudasESAdamisAPCunninghamETJrFeinsodMGuyerDRPegaptanib for neovascular age-related macular degenerationN Engl J Med2004351272805281615625332
   PubMed Web of Science ®Google Scholar
• CruessAFBergerAColleauxKCanadian expert consensus: optimal treatment of neovascular age-related macular degenerationCan J Ophthalmol201247322723522687297
   PubMed Web of Science ®Google Scholar
• BrowningDJKaiserPKRosenfeldPJStewartMWAflibercept for age-related macular degeneration: a game-changer or quiet addition?Am J Ophthalmol2012154222222622813448
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trial1996171112
   PubMedGoogle Scholar
• KodjikianLSouiedEHMimounGRanibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority ranibizumab trialOphthalmology2013120112300230923916488
   PubMed Web of Science ®Google Scholar
• KrebsIVecsei MarlovitsVBodenstorferJComparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degenerationActa Ophthalmologica2013913e178e18323241227
   PubMed Web of Science ®Google Scholar
• LarsenMSchmidt-ErfurthULanzettaPVerteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study resultsOphthalmology20121195992100022424834
   PubMed Web of Science ®Google Scholar
• ChakravarthyUHardingSPRogersCARanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trialOphthalmology201211971399141122578446
   PubMed Web of Science ®Google Scholar
• SubramanianMLAbediGNessSBevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialEye (Lond)201024111708171520885427
   PubMed Web of Science ®Google Scholar
• VallanceJHJohnsonBMajidMABanerjeeSMandalKBaileyCCA randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degenerationEye (Lond)201024101561156720577273
   PubMed Web of Science ®Google Scholar
• BusbeeBGHoACBrownDMHARBOR Study GroupTwelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology201312051046105623352196
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGFineSLComparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• KaiserPKBoyerDSCruessAFSlakterJSPilzSWeisbergerAVerteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI studyOphthalmology201211951001101022444829
   PubMed Web of Science ®Google Scholar
• WilliamsPDCallananDSolleyWAveryRLPiramiciDJAabergTA prospective pilot study comparing combined intravitreal ranibizumab and half-influence photodynamic therapy with ranibizumab in the treatment of neovascular age-related macular degenerationClin Ophthalmol2012615291525
   Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• KrebsISchmettererLBoltzAMANTA Research GroupA randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBr J Ophthalmol201397326627123292928
   PubMed Web of Science ®Google Scholar
• SpaideRFLaudKFineHFIntravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degenerationRetina200626438339016603955
   PubMed Web of Science ®Google Scholar
• BashshurZFHaddadZASchakalAJaafarRFSaabMNoureddinBNIntravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective studyAm J Ophthalmol2008145224925618067876
   PubMed Web of Science ®Google Scholar
• SacuSMichelsSPragerFRandomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term resultsEye (Lond)200923122223222719169239
   PubMed Web of Science ®Google Scholar
• RichRMRosenfeldPJPuliafitoCAShort-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina200626549551116770255
   PubMed Web of Science ®Google Scholar
• TufailAPatelPJEganCBevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyBMJ2010340c245920538634
   PubMed Web of Science ®Google Scholar
• BashshurZFSchakalAHamamRNEl HaibiCPJaafarRFNoureddinBNIntravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degenerationArch Ophthalmol2009125101357136117923543
   PubMedGoogle Scholar
• GhaziNGKnapeRMKirkTQTiedemanJSConwayBPIntravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferationRetina200828568969518463511
   PubMed Web of Science ®Google Scholar
• GoffMJJohnsonRNMcDonaldHRAiEJumperJMFuAIntravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degenerationRetina200727443243817420694
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology20091161576519118696
   PubMed Web of Science ®Google Scholar
• KaiserPKBlodiBAShapiroHAcharyaNRAngiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degenerationOphthalmology2007114101868187517628683
   PubMed Web of Science ®Google Scholar
• MitchellPKorobelnikJFLanzettaPRanibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trialsBr J Ophthalmol201094121319443462
   PubMed Web of Science ®Google Scholar
• ZhangXYGuoXFZhangSDComparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysisInt J Ophthalmol20147235536424790885
   PubMed Web of Science ®Google Scholar
• SolomSDLindsleyKVedulaSSKrzystolikMGHawkinsBSAnti-vascular endothelial growth factor for neovascular age-related macular degenerationCochrane Database Syst Rev20148CD00513925170575
   PubMedGoogle Scholar
• StewartMWClinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on afliberceptClin Ophthalmol201261175118622973088
   PubMedGoogle Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar